RU58841, combined with Dutasteride and topical Minoxidil, is helping users slow hair loss. Long-term users report positive results without significant side effects.
The user has been using topical finasteride and minoxidil for 5 years, with recent use of a liposomal formulation, but sees no significant improvement. They are considering switching to oral treatments due to continued hair loss and thinning.
Users discuss their experiences with finasteride, expressing regret over delayed use due to misinformation and sharing mixed outcomes, including side effects and benefits. Treatments mentioned include finasteride, dutasteride, and minoxidil.
ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.
Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.
The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.
People are discussing switching to Indian generic dutasteride tablets like Dutanol and Dutaheal due to cost concerns, with some users reporting positive results when taken with a high-fat meal. Users have shared experiences with different brands, noting varying effectiveness and side effects compared to finasteride.
Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.
The user is considering liposomal minoxidil due to non-response and side effects from other treatments. They are exploring tretinoin with topical minoxidil as an alternative.
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
The conversation discusses using different concentrations of topical treatments for hair loss, specifically Minoxidil, Finasteride, Dutasteride, and Tretinoin. The user is considering higher concentrations after previous treatments were ineffective.
User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.
The user is using oral Minoxidil 2.5 mg, oral Finasteride 1 mg, and a 2mm derma roller for hair loss but feels discouraged by the lack of results after a month. They are seeking advice and considering additional methods like antiandrogens, exercise, and dietary changes.
The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.
The conversation discusses the effectiveness of finasteride and dutasteride for hair loss, with some users finding no improvement and experiencing side effects. It also mentions the use of RU58841 and topical minoxidil, highlighting that hair sensitivity to DHT varies among individuals.
Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.
A user who attempted to self-administer dutasteride mesotherapy with no success and other users giving their experiences, suggesting the use of treatments such as Minoxidil and Finasteride.
People are frustrated with hair loss treatments like finasteride, minoxidil, and dutasteride, with mixed results and side effects. Some users suggest trying different combinations or doses, while others express disappointment and hope for a cure.
Oleic acid and microneedling are being explored for hair regrowth, but results are mixed. Addressing DHT and fibrosis is crucial, with treatments like finasteride, minoxidil, and scalp massage also discussed.
The results of using Pyrilutamide, a hair loss treatment available on the gray market, and other treatments such as Minoxidil, Finasteride and RU58841.
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.
The user experienced side effects from switching to Dutasteride and is considering whether to lower the Dutasteride dose or return to daily Finasteride. They are uncertain about the best approach due to mixed results from different studies.
PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.
The user is experiencing positive results in hair regrowth using a regimen of 0.5 mg dutasteride, 5 mg oral minoxidil, ketoconazole shampoo, microneedling, and a combination of topical minoxidil with RU58841. They report no side effects and express gratitude for the support and inspiration from the community.
The user discussed switching from RU58841 with Minoxidil to Finasteride due to cost, noting better physical feelings and hair growth with RU58841. They are considering returning to RU58841 and checking DHT levels after a month.
Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.
The conversation discusses new hair loss treatments like stem cell therapy, exosome treatments, and DHI, with mentions of GT20029, Amp303, and Plated PRP Serum as promising options. It also notes the use of dutasteride, topical finasteride, and minoxidil, but the focus is on non-hormonal innovations.
Dutasteride and oral minoxidil are not yielding noticeable results for some users, with some considering alternatives like microneedling or hair transplants. Others report slowed hair loss but no regrowth, and some experience side effects or minimal improvement, leading to frustration and consideration of different treatments.